ARTICLE | Company News
ExonHit, RedPath sales and marketing update
October 4, 2010 7:00 AM UTC
ExonHit said that Highmark Inc., the regional reimbursement arm for Medicare in Delaware, Washington, D.C., Maryland, New Jersey and Pennsylvania, decided to continue coverage of RedPath's PathFinder TG molecular diagnostic assay for pancreatic cancer for indications of pancreatic cyst/mass where first line diagnostic evaluations are inconclusive. ExonHit said it is reviewing the impact of Highmark's decision on its proposed acquisition of RedPath. ...